Zonsen PepLib Biotech and Novartis Sign Worldwide License Agreement regarding Radioligand Therapy Asset
Novartis(US:NVS) Businesswire·2026-01-13 20:07Under the terms of the agreement, PepLib will receive an upfront payment of USD 50 million, with the potential to receive additional development, regulatory, and sales milestone payments, and is also eligible for tiered royalties on future global net sales. About Zonsen PepLib Biotech Inc. ZHUZHOU, China & BOSTON--(BUSINESS WIRE)--Zonsen PepLib Biotech Inc. ("PepLib†) today announced that it has entered into a worldwide license agreement with Novartis for an undisclosed peptide- based asset in the field o ...